BIOLASE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-17: Form 8-K; Period of report 2013-12-11; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 5.02.
- 2013-12-11: Form 8-K; Period of report 2013-12-04; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2013-11-12: Form 8-K; Period of report 2013-11-11; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-09-27: Form 8-K; Period of report 2013-09-23; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-12-17 | 8-K | 2013-12-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On December 12, 2013, the Board of Directors (the "Board") of Biolase, Inc. (the "Company") appointed Director James R. Talevich to the Nominating and Corporate Governance Committee of the Board. 8.01 On December 11, 2013, the Company announced the engagement of Piper Jaffray & Co. to act as the Company's exclusive financial advisor in the evaluation of strategic alternatives. | htm_49001.htm |
| 2013-12-11 | 8-K | 2013-12-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 10, 2013, the Board of Directors (the "Board") of Biolase, Inc. (the "Company") elected Samuel B. Low, D.D.S. and James R. Talevich to the Board. | htm_48946.htm |
| 2013-11-12 | 8-K | 2013-11-11 | 2.02 Results of Operations and Financial Condition | 2.02 On November 11, 2013, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2013. | htm_48803.htm |
| 2013-09-27 | 8-K | 2013-09-23 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_48543.htm |
| 2013-09-19 | 8-K/A | 2013-09-06 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information in Item 1.01 of this Current Report on Form 8-K relating to the Warrant is hereby incorporated into this Item 3.02 by reference. 8.01 On September 10, 2013, the Company issued a press release announcing the Amendment and Warrant disclosed in Item 1.01 above. | htm_48494.htm |
| 2013-09-10 | 8-K | 2013-09-06 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information in Item 1.01 of this Current Report on Form 8-K relating to the Warrant is hereby incorporated into this Item 3.02 by reference. 8.01 On September 10, 2013, the Company issued a press release announcing the Amendment and Warrant disclosed in Item 1.01 above. | htm_48451.htm |
| 2013-09-10 | 8-K | 2013-09-10 | 7.01 Regulation FD Disclosure | 7.01 On September 10, 2013, Alexander K. Arrow, M.D., President and Chief Operating Officer of Biolase, Inc. (the “Company”) will deliver a presentation at the Stifel Nicolaus Healthcare Conference, and will deliver a presentation on September 11, 2013 at the Rodman & Renshaw 15th Annual Global Investment Conference, that will include a written communication comprised of slides. | d595496d8k.htm |
| 2013-08-30 | 8-K | 2013-08-26 | 8.01 Other Events | 8.01 Biolase, Inc. (the "Company") has been notified of class action lawsuits filed against the Company and certain of its executive officers alleging violations of the federal securities laws in connection with statements that the Company filed with or furnished to the Securities and Exchange Commission, or otherwise made available to the public, relating to the Company's financial results for the 2013 second quarter and the Company's recent announcement it had received a waiver from Comerica Bank due to non-compliance with a loan covenant. | htm_48403.htm |
| 2013-08-20 | 8-K | 2013-08-19 | 7.01 Regulation FD Disclosure | 7.01 On August 19, 2013, Biolase, Inc. (the "Company") issued a press release announcing the Company's projection of net cash used in operating activities for the year ending December 31, 2013. | htm_48339.htm |
| 2013-08-07 | 8-K | 2013-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2013, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2013. | htm_48268.htm |
| 2013-06-10 | 8-K | 2013-06-06 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 5.02 On June 7, 2013, the Board elected Frederic H. Moll, M.D. and Erin S. Enright to the Board. | htm_47900.htm |
| 2013-06-07 | 8-K | 2013-06-06 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 6, 2013, the 2013 Annual Meeting of Stockholders of Biolase, Inc. (the "Company") was held at the Company's headquarters, 4 Cromwell, Irvine, California. | htm_47896.htm |
| 2013-05-29 | 8-K | 2013-05-29 | 7.01 Regulation FD Disclosure | 7.01 On May 29, 2013, Frederick Furry, Chief Operating Officer and Chief Financial Officer of Biolase, Inc. (the “Company”) will deliver a presentation at the Stifel, Nicolaus & Company 2013 Jaws & Paws Conference that will include a written communication comprised of slides. | d545971d8k.htm |
| 2013-05-13 | 8-K | 2013-05-07 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_47691.htm |
| 2013-05-07 | 8-K | 2013-05-07 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On May 7, 2013, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2013. 7.01 On May 7, 2013, the Company issued press releases announcing the amendment of its credit facility agreements with Comerica Bank, the consummation of an affiliation agreement with Sun Dental Laboratories, LLC, and the U.S. Patent and Trademark's rejection of all patent claims in the reexamination of the patent related to an infringement lawsuit brought by CAO Group, Inc. against the Company. | htm_47652.htm |
| 2013-03-07 | 8-K | 2013-03-06 | 2.02 Results of Operations and Financial Condition | 2.02 On March 6, 2013, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2012. | htm_47240.htm |
| 2013-01-22 | 8-K | 2013-01-22 | 2.02 Results of Operations and Financial Condition | 2.02 On January 22, 2013, Biolase, Inc. (the "Company") issued a press release announcing preliminary cash flow figures for the fourth quarter ended December 31, 2012. | htm_46923.htm |
| 2013-01-07 | 8-K | 2013-01-07 | 2.02 Results of Operations and Financial Condition | 2.02 On January 7, 2013, Biolase, Inc. (the "Company") issued a press release announcing preliminary revenue figures for the fourth quarter ended December 31, 2012. | htm_46810.htm |
| 2013-01-07 | 8-K | 2013-01-07 | 7.01 Regulation FD Disclosure | 7.01 On January 7, 2013, Frederick Furry, Chief Operating Officer and Chief Financial Officer of Biolase, Inc. (the “Company”) will deliver a presentation at the Sidoti Annual NY Micro Cap Conference that will include a written communication comprised of slides. | d463002d8k.htm |